Lipella Pharmaceuticals Inc.
LIPOOTCHealthcare● Active
$0.10
$-0.01(-4.76%)
Market Cap$462084
P/E Ratio—
52W High$3.17
52W Low$0.02
Lipella Pharmaceuticals Inc. (LIPO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LIPO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.54M | $0.45M | $0.18M | $0.26M | $0.96M |
| Cost of Revenue | $3.61M | $3.04M | $2.55M | $1.46M | $0.98M |
| Gross Profit | ($3.08M) | ($2.59M) | ($2.36M) | ($1.20M) | ($0.01M) |
| Gross Margin %(computed) | -573.65% | -575.87% | — | -461.71% | -1.48% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $2.55M | $1.46M | $0.98M |
| G&A Expenses | $2.00M | $2.16M | $0.23M | $0.72M | $0.04M |
| Total Operating Expenses | $2.00M | $2.16M | $0.23M | $0.72M | $0.04M |
| Operating Income | ($5.08M) | ($4.75M) | ($2.59M) | ($1.92M) | ($0.06M) |
| Operating Margin %(computed) | -947.23% | — | — | -738.71% | -5.91% |
| Interest Income | $0.06M | $0.14M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.01M | $0.01M | $0.01M | $0.01M |
| Income Before Tax | ($5.02M) | ($4.62M) | ($2.60M) | ($1.87M) | ($0.06M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($5.02M) | ($4.62M) | ($2.60M) | ($1.87M) | ($0.06M) |
| Net Margin %(computed) | -935.25% | — | — | -719.30% | -6.41% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-4.79 | $-6.16 | $-5.12 | $-4.00 | $-0.23 |
| Wtd Avg Shares | 1.05M | 0.75M | 0.51M | 0.47M | 0.27M |
| EBITDA | ($5.01M) | ($4.61M) | ($2.59M) | ($1.86M) | ($0.05M) |
| EBITDA Margin %(computed) | -934.71% | — | — | -716.66% | -5.58% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Lipella Pharmaceuticals Inc. data
About Lipella Pharmaceuticals Inc. (LIPO) Income Statement
Lipella Pharmaceuticals Inc. (LIPO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, LIPO reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -573.65%), and net income of ($0.01B) — a net profit margin of -935.25%.
Frequently asked questions
LIPO · 4 questionsLipella Pharmaceuticals Inc. (LIPO) reported revenue of $0.00B for 2024, up 19.3% year-over-year.
LIPO revenueLIPO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09